BT-474 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Breast cancer cell lines |
| Organism |
Human |
| Donor History |
Invasive ductal carcinoma |
| Growth Properties |
The cells grow in compact ,slowly growing multi-layered colonies which rarely become confluent. A confluent monolayer is not formed. |
| Growth Conditions |
Culture medium: DMEM:Ham's F12 (1:1) ,w: 3.1 g/L Glucose ,w: 2.5 mM L-Glutamine ,w: 15 mM HEPES ,w: 0.5 mM Sodium pyruvate ,w: 1.2 g/L NaHCO3 (Cytion article number 820400a). Supplements: Supplement the medium with 10% FBS ,10 microgram/mL Insulin. Seeding density: 2 x 10⁴ cells/cm² will yield in a mostly confluent layer in about 4 days. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
BT-474 is a human breast cancer cell line, derived from the ductal carcinoma of a 60-year-old female. This cell line is estrogen and progesterone receptor positive, making it a valuable model for studying hormone-responsive breast cancers. BT-474 cells are also characterized by the overexpression of HER2/neu (human epidermal growth factor receptor 2), a protein that is amplified and plays a critical role in the pathogenesis and progression of certain aggressive types of breast cancer.
The BT-474 cell line is extensively used in oncological research to study the molecular mechanisms of breast cancer proliferation and to test therapeutic strategies targeting hormone receptors and the HER2 pathway. These cells are particularly useful for examining the efficacy of HER2-targeted therapies, such as trastuzumab (Herceptin), and for exploring mechanisms of resistance to these treatments. The cell line has also contributed to advancements in understanding how hormonal manipulations affect cancer cell growth and survival, providing insights into potential treatment approaches for hormone-dependent tumors.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

